Project Grant P18AP00027

The federal Project Grant award of $1,500,000 was provided by the Health Resources and Services Administration (HRSA) under the Health Center Program (CFDA 93.224). The grant aims to "ACCELERATE CANCER SCREENING" by partnering the Bronx Community Health Network (BCHN) with the Montefiore Einstein NCI-Designated Cancer Center (MECC) to improve colorectal cancer screening and follow-up care in the Bronx, New York. The key objectives are to: 1) Increase colorectal cancer screening rates...

This Project Grant award of $1,475,079 from the Health Resources and Services Administration (HRSA) under the Health Center Program (CFDA 93.224) aims to accelerate colorectal cancer (CRC) screening and referral for care and treatment in underserved areas of Philadelphia. The prime awardee, Resources For Human Development, Inc. (RHD), will collaborate with the Abramson Cancer Center, Spectrum Health Services, and the Health Federation of Philadelphia to increase CRC screening rates by over 1,000...

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $260,250.00 to Health Research, Inc., a not-for-profit research organization in Buffalo, NY, to investigate "The Role of SLC45A3-ELK4 Chimera as a Molecular Determinant of Prostate Cancer Health Disparity." The award commenced on March 15, 2025 and is scheduled for completion by March 14, 2027. This research aims to advance the understanding...

This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...

This Project Grant award of $1,498,179.00 from the Health Resources and Services Administration (HRSA) Health Center Program (CFDA 93.224) is intended to accelerate cancer screening and referral rates for breast, colorectal, and cervical cancer in an underserved patient population served by Lone Star Family Health Center in Montgomery, Harris, and Walker Counties, Texas. The award supports a partnership between Lone Star Family Health Center, a Federally Qualified Health Center (FQHC), and MD...

The National Cancer Institute (NCI) awarded a 5-year, $629,068 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Albert Einstein College of Medicine to conduct an implementation study of integrated human papillomavirus (HPV) self-sampling in HIV care centers in Ethiopia. The study aims to leverage the Project ECHO (Extension for Community Healthcare Outcomes) virtual learning platform to promote experience sharing and technical assistance across 5 hospitals to improve...

The U.S. Department of Health and Human Services, through the Health Center Program (CFDA 93.224), awarded a $1,000,000 Project Grant to Sunset Park Health Council, Inc. dba Family Health Centers at NYU Langone (FHC-NYUL) to increase breast and colorectal cancer screening and enhance referral pathways to treatment for underserved, under-resourced, and marginalized patient populations, including the underhoused, in shelters, and homeless, in the Southwest area of Brooklyn, New York. The...

This Project Grant award of $1,500,000 from the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), under the Health Center Program (CFDA 93.224), will enable Gulf Coast Health Center, Inc., a Federally Qualified Health Center (FQHC) in Port Arthur, Texas, to increase outreach and access to colorectal cancer screening services. The project aims to raise the colorectal cancer screening rate from 3% to 25% in the first year and 40% in the second...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

This Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will fund the establishment of the Human Prostate Tumor Atlas Center (HPTAC) at Washington University in St. Louis. The $1,032,520 award, effective September 1, 2024 through August 31, 2029, will support the development of a molecularly resolved spatial atlas of prostate cancer (PCa). The atlas will integrate multi-omics, imaging, and...